9.52 0.00 (0.00%)
After hours: 5:01PM EST
|Bid||9.20 x 1200|
|Ask||10.32 x 800|
|Day's Range||9.26 - 10.32|
|52 Week Range||9.26 - 22.80|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.60|
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
The Berkeley, California-based company said it had a loss of 65 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Conference Call to be held Today at 4:30pm ET/1:30pm PT BERKELEY, Calif., Nov. 05, 2018 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for.
BERKELEY, Calif., Oct. 29, 2018 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September.
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative.
HENDERSON, NV / ACCESSWIRE / October 18, 2018 / Below are a few Medical stocks that are in position to make their investors major profit in the coming sessions.The company on our radar today, however, ...
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Dynavax Technologies Corporation (DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA® (pembrolizumab) will be evaluated in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. SD-101 is expected to augment responses to anti-PD-1 therapy as has been reflected in early clinical studies of other tumor types.
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
BERKELEY, Calif., Oct. 09, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating.
Nobel Prize winner Jim Allison is in Texas, but the Nobel Prize win Monday for his cancer immunotherapy work reverberates in the Bay Area.
BERKELEY, Calif., Sept. 27, 2018-- Dynavax Technologies Corporation today announced that Eddie Gray, Dynavax’ s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on ...